HTB

FDA fails to approve long-acting cabotegravir/rilpivirine (Cabenuva) injections due to unspecified manufacturing concerns

Simon Collins, HIV i-Base

On 21 December 2019, ViiV Healthcare issued a press release on the recent FDA decision not to approve cabotegravir/rilpivirine (CAB/RPV LA) long-acting injections.

This was unexpected, given that CAB/RPV LA had successfully completely phase 3 studies (ATLAS and FLAIR), showing high efficacy and low side effects in these studies. CAB/RPV was non-inferior to standard of care combinations in treatment-naive and switch studies and reported improved quality of life compared to oral combinations in study participants.

Instead, the FDA has issued a complete response letter relating to chemistry and manufacturing controls (CMC), but the press statement emphasises that there are no new safety concerns for these compounds.

The letter itself has not been published and specific details about these concerns are not yet available.

Cabotegravir is an integrase inhibitor developed by ViiV Healthcare and rilpivirine is an NNRTI developed by Janssen Sciences. Development of CAB/RPV long-acting combination led by ViiV, with the brand name Cabenuva.

comment

The understatement in the letter is that ViiV are working with the FDA to resolve these issues. Phase 3 results meant that approval was expected, so this will hopefully be a short delay that can be resolved.

There has always been high interest in options for HIV treatment other than oral medicines and this announcement is likely to just extend the time a little longer before these become available.

However, certainly for people in the UK, access will depend on many factors, including cost.

There are many potential benefits from injectable ART, as least for people who have difficulty with pills, and this will also provide new options for how HIV treatment is delivered.

Reference

ViiV Healthcare press statement. ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV. (21 December 2019).
https://viivhealthcare.com/en-gb/media/press-releases/2019/december/complete-response-letter-from-us-fda

 

Links to other websites are current at date of posting but not maintained.